An American senator said that a GLP-1 drug changed his life, and is now asking for generalized access to obesity medications.
In an opinion article of the New York Times on April 8, Senator John Fetterman, D-Pa., He wrote about his experience with Mounjaro (Tirzepatide).
The injectable prescribed medication is mainly used to treat type 2 diabetes.
Fetterman received the medicine in July 2024.
“As a stroke survivor, I was interested in studies that show [Mounjaro] It could significantly reduce the risk of great heart events, “wrote the senator.
“Although I began to take it for the health of the heart, I was surprised how much it has made me feel in all areas. It has had a significant impact on my general health,” he continued.
“The pains, the pains and the rigidity have disappeared. Physically, I feel a younger decade, as well as clearer and more optimistic than in years. As for side effects, I have also lost about 20 pounds.”
Beyond the reduction of blood sugar, GLP-1 medications have also been related to a variety of other benefits, including the best health of the heart, neurological function and metabolic health, as Fox News Digital reported.
Eli Lilly, Maker or Mounjaro, also sacrifices another version of the medicine called Zepbound, which is the same medication approved for weight loss, chronic weight control and sleep apnea.
Other GLP-1 medications include Ozempic, Wegovy, Victaza, Saxenda, all manufactured by Novo Nordisk.
Fetterman said that GLP-1 medications have been found to have beneficial effects on cholesterol, heart rate and cardiac inflammation.
“Some recent studies suggest that they could even help stop alcohol addiction and support cognitive function, potentially slowing down or avoiding conditions such as Parkinson and Alzheimer’s Parkinson,” Hey in the Times opinion article.
“Physically, I feel a younger decade, as well as clearer and more optimistic than in years.”
In the opinion article, Fetterman requested expanded access to these mediations, which can cost up to $ 1,000 from their pocket if they are not covered by insurance.
“Currently, Medicare covers drugs only in specific circumstances, such as diabetes or cured heart risk,” he wrote. “And Medicaid coverage is even more limited.”
Fetterman added that he was not compensated for sharing his experience.
“I am only a guy who has benefited from thesis medications and movements to ensure that any other person who can benefit from them can also have access to them,” hey.
While Fetterman shares HHS Sec. The opinions of Robert F. Kennedy Jr. to prioritize nutrition and healthy life, he said he believes that mediations are necessary for some.
“I totally agree that diet and lifestyle are important, much. But the diet itself is not enough,” he wrote.
“For the millions of Americans fighting with serious health problems, medicines can be a first crucial step to register enough health control to start making significant changes in lifestyle.”
Doctors discuss benefits and access
Dr. Marc Siegel, Clinical Professor of Medicine at the Senior Medical Analyst of Nyu Langone Health and Fox News, said that semaglutidos, including Ozempic and Wogovy, are “very important medications” for type 2 diabetes, with an increasing use of obesity.
“Throughout medications seem to have beneficial uses for the profile of the heart and lipids, and also for the brain and the reduction of the risk of dementia: the studies are in -and, and more data is still needed,” he told Fox News Digital.
The first approach to obesity is the changes in the lifestyle, including exercise, improved diet and optimal dream, Siegel said.
“That said, these weight loss medications (including Zepbound) are also good tools when lifestyle is not enough,” he said.
“They help prevent low -line diseases such as heart disease, stroke, high blood pressure and sleep apnea, which tend to come from obesity.”
He added: “In general, we are saving money to the health system, so I would like to see that Medicare and Medicaid approach them for diabetes and weight loss.”
Dr. Brett Osborn, a Florida neurologist and longevity expert, said he has been recipes GLP-1 to his patients since 2019.
“Mounjaro and its cousins are not just weight loss tools, they are metabolic restart buttons,” he told Fox News Digital.
“People with metabolic syndrome do not need conferences on the curly and the importance of exercise. They need help.”
Osborn agreed that the lifestyle is essential, but it is “rarely enough.”
“LPG-1 give the patient’s impulse by rolling the ball,” he said. “And when that happens, health habits are formed. The diet improves. The movement improves. People begin to feel the benefits of a healthy life.”
Osborn said thesis measurements are not cosmetic, but therapeutic.
“I have seen what they can do first hand: reductions in body fat, inflammation, glucose, triglycerides and insulin resistance, and with them, significant reductions in the incidence of stroke and heart attack.”
“I think this is a signal directed directly to Big Pharma.”
The administration of President Donald Trump recently announced that Medicare and Medicaid would not cover the medications, as the Medicare and Medicaid service centers said on Friday night.
Osborn said the movement to block coverage probably has nothing to do with efficiency.
“Trump knows that these mediations work,” said Osborn. “I think this is a signal directed directly to Big Pharma:” Lower the price or medicine, the largest buyer in the block, is out. “
“This is not a dismissal, it is leverage,” said Osborn, affirming his opinion on the matter. “President Trump will probably negotiate until the” price is correct “, digging up Big Pharma while improving with the health of Americans.”
